Dr. Sarah L. Renfert, MD

Dr. Renfert practices at Total Access Urgent Care in Saint Charles, Missouri.

Dr. Renfert's NPI, 1932171600, was assigned on February 6, 2006. Dr. Renfert holds Missouri license 2000163032.

Dr. Renfert's primary practice is Total Access Urgent Care, at 2138 1 Capitol Dr, Saint Charles, MO 63301 in Saint Charles County. The practice phone is (314) 961-2255.

Dr. Renfert's primary practice is Total Access Urgent Care in Saint Charles, Missouri. Dr. Renfert is also affiliated with St. Luke's Hospital. The medical group on file is Total Access Urgent Care. Dmand AI also links Dr. Renfert to 4 more medical groups, 2 group practices and clinics and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Renfert practices, 4 sites in all. Vendor and product names are available with a free account.

Emergency medicine is Dr. Renfert's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dr. Renfert is licensed in Missouri.

CMS data shows 130 Medicare services from Dr. Renfert across 3 procedure codes in 2024, all of them office visits, for 111 Medicare patients. Medicare paid $7,533 for them. Every service was in an office.

CMS counts 111 Medicare patients who saw Dr. Renfert in 2024. The largest group is 65 to 74, with 48 patients. 65% of them have high blood pressure, and 63% have high cholesterol. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Renfert's median patient age at 44, with 60% women.

In 2024, Dr. Renfert wrote 2,864 Medicare Part D claims for 349 patients. 91% of them were for generic drugs. CMS names the drug for 2,204 of them, across 70 drugs with 11 or more claims each, at $47,710 in total drug cost. In 2023, CMS named 1,539 claims across 57 drugs.

Dr. Renfert accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 269 general payments to Dr. Renfert from 28 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,382.